TENX - Tenax Therapeutics Inc logo

Tenax Therapeutics Inc

TENX

Tenax Therapeutics develops cardiopulmonary therapies in the U.S., focusing on treatments for pulmonary hypertension and heart failure. Its pipeline includes TNX-101, TNX-102, and TNX-201, aimed at addressing serious cardiovascular and oncological conditions.

โš•๏ธ Healthcare NASDAQ Listed 1997 $ USD
$1,000 invested 30 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth-23.32%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-99.74%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-47.67%
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency
20 Years
Score1.3
Net Growth-17x
Net Trend30%
Net Income Consistency
Rev Growth100.00%
Rev Trend17%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-31x
Net Trend28%
Net Income Consistency
Rev Growthโ€”
Rev Trend14%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Tenax Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. TENX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 1.89โ€”
1 Year2025-09-30
$ 7.61-75.16%
5 Years2021-09-30
$ 2.83K-99.93%
10 Years2016-09-30
$ 74.08K-100.00%
20 Years2006-09-29
$ 1000K-100.00%
30 Years1996-09-30
$ 1000K-100.00%
All Time1997-01-02
$ 1000K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 64M$ 117M
2025$ 0.00-$ 52M$ 97M
2024$ 0.00-$ 17M$ 94M
2023$ 0.00-$ 7M$ 9M
2022$ 0.00-$ 11M$ 2M
2021$ 0.00-$ 32M$ 5M
2020$ 0.00-$ 9M$ 6M
2019$ 0.00-$ 8M$ 5M
2018$ 0.00-$ 6M$ 12M
2017$ 0.00-$ 8M$ 7M
2016$ 0.00-$ 43M$ 13M
2015$ 49.29K-$ 14M$ 20M
2014$ 49.29K-$ 14M$ 58M
2013$ 288.73K-$ 19M$ 58M
2012$ 288.73K-$ 19M$ 6M
2011$ 415.03K-$ 15M$ 3M
2010$ 322.35K-$ 10M$ 632.71K
2009$ 47.39K-$ 10M$ 2M
2008-$ 6M$ 4M
2007-$ 24.13K-$ 3M$ 940.24K
2006-$ 25.63K-$ 3M$ 382.00
2005-$ 25.63K-$ 2M$ 588.76K
2004-$ 2M$ 1M
2003-$ 2M$ 722.54K
2002-$ 3M$ 524.43K
2001$ 1.00-$ 1M$ 2M
2000$ 1.00-$ 1M$ 5M
1999$ 1.00-$ 911.34K$ 200K
1998$ 1.00-$ 800K$ 740.22K
IPO1997-$ 1M$ 53.86K
TENX - Tenax Therapeutics Inc logo

Tenax Therapeutics Inc fundamental performance

Between 2005 and 2025, revenue went from -$ 25.63K to $ 0.00 and net income went from -$ 2M to -$ 52M. Revenue increased in 3 of those 20 years; net income in 6.

Tenax Therapeutics Inc currently holds a 20-year HDB Score of 1.3 out of 10. How the HDB Score is calculated.

Membership

Explore TENX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies